|1.||Byun, Dong-Won: 1 article (11/2013)|
|2.||Mok, Ji Oh: 1 article (11/2013)|
|3.||Kim, Sang Jin: 1 article (11/2013)|
|4.||Jung, Chan Hee: 1 article (11/2013)|
|5.||Suh, Kyo Il: 1 article (11/2013)|
|6.||Kim, Chul Hee: 1 article (11/2013)|
|7.||Park, Hyeong Kyu: 1 article (11/2013)|
|8.||Kim, Yeo Joo: 1 article (11/2013)|
|9.||Yoo, Myung Hi: 1 article (11/2013)|
|10.||Ryu, Chang Beom: 1 article (11/2013)|
11/01/2012 - "Maxmarvil was found to be safe, well tolerated and effective in osteoporosis treatment. "
11/01/2013 - "Therefore, this study suggested that enteric-coated Maxmarvil is less harmful to gastrointestinal mucosa than alendronate, and may improve the tolerability of osteoporosis medication in clinical practice."
12/01/2006 - "A total of 217 postmenopausal women with osteoporosis were enrolled; 199 patients were randomly assigned to one of two treatment groups (Maxmarvil group or alfacalcidol group). "
11/01/2012 - "The efficacy and safety of a combined alendronate and calcitriol agent (maxmarvil): a postmarketing surveillance study in korean postmenopausal women with osteoporosis."
|2.||Wounds and Injuries (Trauma)
11/01/2013 - "Gastric mucosal injuries developed in eight subjects in the alendronate group and four subjects in the Maxmarvil group; this difference was statistically significant. "
11/01/2013 - "Esophageal mucosal injuries developed in two of 16 subjects in the alendronate only group and 0 of 17 in the Maxmarvil group. "
|1.||Alendronate (Alendronate Sodium)